Growth Metrics

Palvella Therapeutics (PVLA) EBT Margin (2016 - 2024)

Palvella Therapeutics has reported EBT Margin over the past 9 years, most recently at 4622.87% for Q3 2022.

  • Quarterly EBT Margin fell 415434.0% to 4622.87% in Q3 2022 from the year-ago period, while the trailing twelve-month figure was 213.82% through Sep 2022, up 2967.0% year-over-year, with the annual reading at 145.58% for FY2021, 944.0% up from the prior year.
  • EBT Margin was 4622.87% for Q3 2022 at Palvella Therapeutics, up from 5303.48% in the prior quarter.
  • Over five years, EBT Margin peaked at 3.0% in Q2 2018 and troughed at 5303.48% in Q2 2022.
  • The 5-year median for EBT Margin is 130.34% (2021), against an average of 798.18%.
  • Year-over-year, EBT Margin soared 196987bps in 2019 and then plummeted -479334bps in 2022.
  • A 5-year view of EBT Margin shows it stood at 1974.33% in 2018, then skyrocketed by 100bps to 4.46% in 2019, then tumbled by -18202bps to 817.06% in 2020, then soared by 84bps to 130.34% in 2021, then crashed by -3447bps to 4622.87% in 2022.
  • Per Business Quant, the three most recent readings for PVLA's EBT Margin are 4622.87% (Q3 2022), 5303.48% (Q2 2022), and 67.89% (Q1 2022).